Holen Sie sich die Stockscreener-App
9.12
1.30%
-0.12
Handel nachbörslich:
9.12
Schlusskurs vom Vortag:
$9.24
Offen:
$9.3
24-Stunden-Volumen:
266.14K
Relative Volume:
0.86
Marktkapitalisierung:
$470.78M
Einnahmen:
$227.18M
Nettoeinkommen (Verlust:
$24.38M
KGV:
19.10
EPS:
0.4774
Netto-Cashflow:
$53.60M
1W Leistung:
+3.40%
1M Leistung:
+14.29%
6M Leistung:
+21.76%
1J Leistung:
+73.71%
1-Tages-Spanne:
$8.99
$9.30
1-Wochen-Bereich:
$8.80
$9.51
52-Wochen-Spanne:
$4.30
$9.51
Puma Biotechnology Inc Stock (PBYI) Company Profile
Firmenname
Puma Biotechnology Inc
Sektor
Branche
Telefon
(424) 248-6500
Adresse
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
9.12 | 470.26M | 227.18M | 24.38M | 53.60M | 0.4774 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Underperform |
| 2019-10-08 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-10 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-01-17 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2019-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-11-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-11-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Eingeleitet | Goldman | Sell |
| 2018-05-11 | Bestätigt | Stifel | Buy |
| 2017-11-10 | Bestätigt | Citigroup | Buy |
| 2017-11-10 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Bestätigt | Stifel | Buy |
| 2017-09-11 | Bestätigt | Credit Suisse | Outperform |
| 2017-07-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-06-06 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Bestätigt | RBC Capital Mkts | Sector Perform |
Alle ansehen
Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten
Puma (PBYI) Latest Quarter: The Available Earnings Metric Delivers a Beat; Investor Response: The Stock Ends Down 4.00% for the Current SessionEarnings Turnaround - vinanet.vn
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript - AOL.com
Puma (PBYI) Latest Quarter: EPS Lands Above Forecast in the Current Update; Trading Move: Shares Move 4.76% Up in the Latest SessionEPS Growth Report - vinanet.vn
Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen - MarketBeat
Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now? - Yahoo Finance
Puma Biotechnology, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:PBYI) 2026-08-10 - Seeking Alpha
Puma Biotechnology Reports $56.5M Revenue and Profitability in Q2 - sekbernews.id
Puma Biotechnology (PBYI) Stock Jumps On Profit Strength As Earnings Outlook Fades - Sahm
Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Puma Biotech earnings beat by $0.16, revenue topped estimates - Investing.com Nigeria
TD Cowen Forecasts Strong Price Appreciation for Puma Biotechnology (NASDAQ:PBYI) Stock - marketbeat.com
Transcript : Puma Biotechnology, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised - Yahoo Finance
Puma Biotechnology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Puma Biotechnology’s Douglas M. Hunt sells $69,904 in shares - Investing.com
Puma Biotechnology Q2 Earnings Call Highlights - MarketBeat
Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ... - finance.yahoo.com
Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Earnings call transcript: Puma Biotechnology tops Q2 2026 estimates as profit returns - Investing.com
Puma Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Puma Biotech: Q2 Earnings Snapshot - aol.com
PUMA BIOTECHNOLOGY, INC. 2026: Revenue $56.5M, EPS $0.16— 10-Q Summary - TradingView
Puma Biotechnology Reports Second Quarter 2026 Financial Results - marketscreener.com
Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter of 2026 - marketscreener.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Finviz
Puma Biotechnology Inc expected to post earnings of 4 cents a shareEarnings Preview - TradingView
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results - The National Law Review
Puma Biotechnology (PBYI) Gains 1.43% to $7.8, Holds Above Key Support at $7.41PCR Mean Reversion - dars.gov.et
Renaissance Technologies LLC Cuts Position in Puma Biotechnology, Inc. $PBYI - MarketBeat
Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline - Yahoo Finance
Puma Biotechnology (PBYI) Slips 1.88% as Stock Tests Key Support LevelsSMA Signal - dars.gov.et
Puma Biotechnology Inc Revenue Breakdown – NASDAQ:PBYI - TradingView
Puma Biotechnology Inc (PBYI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Puma Biotechnology Inc (PBYI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Puma Biotechnology Inc (PBYI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ETFs Investing in Puma Biotechnology, Inc. Stocks - TradingView
PBYI|Puma Biotechnology Inc|Price:7.980|Chg%:-0.030 - TradingKey
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results - WBOC TV
Puma Stock Puma Biotechnology Inc Discount Puma Biotechnology Acquisition Outlet Online PUMA Biotechnology Form S - มูลนิธิเพื่อผู้บริโภค มพบ.
Puma Biotechnology’s Douglas M. Hunt sells $69,904 in shares By Investing.com - Investing.com Nigeria
Puma biotechnology CFO Maximo Nougues sells $77,556 in stock By Investing.com - Investing.com South Africa
Form 4 Puma Biotechnology Inc For: 8 July By Investing.com - Investing.com Nigeria
Alan Auerbach, Puma Biotechnology president and CEO, sells $364,051 By Investing.com - Investing.com South Africa
Puma Biotechnology (PBYI) CEO sells 44,058 shares under 10b5-1 plan - Stock Titan
Puma Biotechnology (PBYI) CFO sells 9,386 shares in 10b5-1 trade - Stock Titan
Alan Auerbach, Puma Biotechnology president and CEO, sells $364,051 - Investing.com
Form 144 PUMA BIOTECHNOLOGY For: 6 July By Investing.com - Investing.com Nigeria
[144] PUMA BIOTECHNOLOGY, INC. SEC Filing - Stock Titan
Puma Biotechnology (PBYI) Faces Resistance as Shares Pull Back Toward Key SupportMarket Neutral Pair - dars.gov.et
Price to sales forward of Puma Biotechnology Inc – NASDAQ:PBYI - TradingView
Finanzdaten der Puma Biotechnology Inc-Aktie (PBYI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Puma Biotechnology Inc-Aktie (PBYI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HUNT DOUGLAS M | See Remarks |
Jul 06 '26 |
Sale |
8.26 |
8,460 |
69,905 |
196,841 |
| NOUGUES MAXIMO F | Chief Financial Officer |
Jul 06 '26 |
Sale |
8.26 |
9,386 |
77,557 |
230,637 |
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):